LifeSci Capital Remains a Buy on Ibio (IBIO)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital's Patrick Dolezal has maintained a Buy rating on Ibio (IBIO) with a price target of $5.00. The analyst consensus for Ibio is a Strong Buy, with an average price target of $5.80. Dolezal has an average return of 15.0% and a 43.63% success rate on his stock recommendations.
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Neurogene, and Rocket Pharmaceuticals. According to TipRanks, Dolezal has an average return of 15.0% and a 43.63% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ibio with a $5.80 average price target.